Jennifer Sun, MD
Ophthalmology · Boston, MANPI 1619083482
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 82.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $26,796 and has fallen 99.6% since, to $112 in 2024. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 25 payments — averaging $1256.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$26K
- Genentech, Inc.$3K
- Novo Nordisk AS$2K
- Merck$796
- Alcon$279
- Alimera Sciences, Inc.$4
Across 35 payments — averaging $119,023 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$4M
- Genentech, Inc.$124K
- Boehringer Ingelheim$32K
- Novartis$7K
- Novo Nordisk$2K
- Boehringer Ingelheim Finland Ky$187
What the payments were for
- Consulting fees$14,51546%
- Travel & lodging$15,51249%
- Food & beverage$1,3764%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $25,885 |
| Genentech, Inc. | 4 | $2,705 |
| Novo Nordisk AS | 4 | $1,734 |
| Merck | 5 | $796 |
| Alcon | 2 | $279 |
| Alimera Sciences, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Constellation$167
- Clareon$112
How this compares
$31,403 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate | 24 | $1,857 |
| Latanoprost | 64 | $767 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 13 | $393 |
| Timolol Maleate | 21 | $330 |
| Dorzolamide Hcl | 13 | $222 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Boston
- Rishi SinghBoston$1.7M
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Dean EliottBoston$250K
- Mina FarahaniBoston$227K
- Jia YinBoston$173K
- John MillerBoston$106K
- Elizabeth RossinBoston$101K
- Suzanne FreitagBoston$96K
- Nimesh PatelBoston$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.